ClinicalTrials.gg

Program

VP-102

Also written as “VP-102 - Cantharidin, Topical Film Forming Solution”, “VP-102 (US) / TO-208 (Japan)” and “VP-102 and applicator”.

Its studies are mostly in Warts · Molluscum Contagiosum · Condylomata Acuminata, led by Verrica Pharmaceuticals.

Furthest: phase 3, since Dec 13, 20178 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Verrica Pharmaceuticals83 open or runningphase 3since Dec 13, 2017Jun 12, 2017Nov 2026phase 3 · NCT07246590

Also a collaborator on its studies: canfield-scientific-inc, medidata-solutions, veeva-systems, allucent-us-llc, myonex, cmic-co-ltd-japan, paidion-research-inc, bioclinica-inc, almac-clinical-services, database-integrations-inc, cato-research and instat-services.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2017First study: phase 2 study in Molluscum ContagiosumFirst studyNCT03186378 · 33 enrolled · United States
  2. Dec 13, 20172 phase 3 studies in Molluscum ContagiosumNCT03377803, NCT03377790
  3. Mar 21, 2018Phase 2 study in WartsNCT03487549 · 56 enrolled · United States
  4. Jun 6, 2019Phase 2 study in Condylomata AcuminataNCT03981822 · 105 enrolled · United States
  5. Nov 17, 2025Phase 3 study in WartsNCT07246590 · 302 enrolled · United States
  6. May 27, 2026Phase 3 study in WartsNCT07637734 · 300 planned · United States, Japan
  7. Oct 13, 2026Phase 2 study in WartsNCT07881952 · 30 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 3 study in WartsNCT07246590
  2. Apr 2027Primary completion: phase 2 study in WartsNCT07881952
  3. May 2027Primary completion: phase 3 study in WartsNCT07637734

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07881952Warts · United States2Not yet recruitingApr 202730
NCT07637734Warts · United States, Japan3RecruitingMay 2027300
NCT07246590Warts · United States3Active, not recruitingNov 2026302
NCT03981822Condylomata Acuminata · United States2CompletedMay 21, 2020105
NCT03487549Warts · United States2CompletedMay 16, 201956
NCT03377803Molluscum Contagiosum · United States3CompletedSep 26, 2018262
NCT03377790Molluscum Contagiosum · United States3CompletedNov 26, 2018266
NCT03186378Molluscum Contagiosum · United States2CompletedJun 25, 201833

How it is read

Names in the registry

  • “VP-102”, 2 entries
  • “VP-102 - Cantharidin, Topical Film Forming Solution”, 2 entries
  • “VP-102 (US) / TO-208 (Japan)”, 1 entry
  • “VP-102 and applicator”, 1 entry
  • “VP-102 Cantharidin topical film forming solution”, 1 entry

Codes read as this program: VP102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.